179 related articles for article (PubMed ID: 38137564)
1.
Danishevich A; Bilyalov A; Nikolaev S; Khalikov N; Isaeva D; Levina Y; Makarova M; Nemtsova M; Chernevskiy D; Sagaydak O; Baranova E; Vorontsova M; Byakhova M; Semenova A; Galkin V; Khatkov I; Gadzhieva S; Bodunova N
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137564
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
3. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.
Soura E; Eliades PJ; Shannon K; Stratigos AJ; Tsao H
J Am Acad Dermatol; 2016 Mar; 74(3):395-407; quiz 408-10. PubMed ID: 26892650
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.
Cremin C; Howard S; Le L; Karsan A; Schaeffer DF; Renouf D; Schrader KA
Hered Cancer Clin Pract; 2018; 16():7. PubMed ID: 29541281
[TBL] [Abstract][Full Text] [Related]
5. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
Goldstein AM
Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
[TBL] [Abstract][Full Text] [Related]
6. Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).
Noë M; Hackeng WM; de Leng WWJ; Vergeer M; Vleggaar FP; Morsink FHM; Wood LD; Hruban RH; Offerhaus GJA; Brosens LAA
Am J Surg Pathol; 2019 Sep; 43(9):1297-1302. PubMed ID: 31261289
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
8. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
9. Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of
Pauley K; Khan A; Kohlmann W; Jeter J
Front Oncol; 2022; 12():837057. PubMed ID: 35372037
[TBL] [Abstract][Full Text] [Related]
10. Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.
Jeong AR; Forbes K; Orosco RK; Cohen EEW
J Otolaryngol Head Neck Surg; 2022 Feb; 51(1):5. PubMed ID: 35123577
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
Arnaut JRMB; Guimarães IDS; Dos Santos ACE; Rodrigues EM; Machado JRDS; de Melo AC
Int J Dermatol; 2023 Aug; 62(8):1060-1066. PubMed ID: 37322831
[TBL] [Abstract][Full Text] [Related]
12. Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity.
Lynch HT; Shaw TG
Fam Cancer; 2016 Jul; 15(3):487-91. PubMed ID: 26892865
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
14. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
15. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
Sargen MR; Merrill SL; Chu EY; Nathanson KL
Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
[TBL] [Abstract][Full Text] [Related]
18. Familial pancreatic cancer.
Lynch HT; Lynch JF; Lanspa SJ
Cancers (Basel); 2010 Nov; 2(4):1861-83. PubMed ID: 24281205
[TBL] [Abstract][Full Text] [Related]
19.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
20. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
